GRI Bio Unveils Phase 2a Biomarker Data Showing Repair Phenotype in IPF

summarizeSummary

GRI Bio presented new Phase 2a biomarker data at ERS 2026 showing GRI-0621 drives a repair phenotype in IPF across nine mechanistic pillars, with placebo-adjusted FVC gains of +99 mL overall and +139 mL on background SOC.

check_boxKey Events · Product Development and Regulatory · GRI

• Nine Mechanistic Pillars Defined

  New translational data from the Phase 2a GRI-0621-IPF-02 study integrated four independent modalities — whole-blood RNA sequencing (18 of 72 anchor transcripts at FDR<0.05), 28-color spectral flow cytometry (13 readouts at p<0.05), serum ECM biomarkers, and clinical readouts — each pillar supported by direction-consistent signals from at least two modalities.

• FVC Improvement vs Placebo

  Placebo-adjusted FVC change from baseline at Week 12 was +99 mL overall and +139 mL on background SOC antifibrotic therapy. 39% of GRI-0621 patients experienced ≥30 mL FVC increase vs 20% placebo (50% in SOC subset), and only 8% experienced ≥10% FVC decline vs 20% placebo — a 60% relative reduction.

• Repair Phenotype Evidence

  Serum PRO-C4/C4Ma3 shifted +13.6 percentage points toward net basement-membrane repair, with RNA-seq upregulation of COL4A1/A2, LAMA3, COL17A1, and AT2-to-AT1 re-epithelialization markers (ALDH1A2, NAPSA, SFTPB, AQP5, AGER). Fibrillar collagen ratios shifted toward net fibrolysis (PRO-C3/C3M −13.6, PRO-C6/C6M −14.0).

• Favorable Safety Profile

  No serious treatment-emergent adverse events (0% vs 8% placebo), no drug-related serious AEs, and lower rates of cough (0% vs 25%), dyspnea (4% vs 17%), and diarrhea (17% vs 33%) despite higher background nintedanib use in the active arm. No hepatic, lipid, visual, auditory, or neuropsychiatric safety signals.

auto_awesomeAnalysis · GRI · Life Sciences

GRI Bio presented new translational biomarker data from its Phase 2a GRI-0621-IPF-02 study at ERS 2026, integrating four independent measurement modalities from the same 35-patient population. The data define nine mechanistic pillars — immune re-balancing, myofibroblast inhibition, fibrolysis, basement-membrane repair, re-epithelialization, FVC stabilization, antitussive effect, and GI protection — each supported by direction-consistent signals from at least two modalities. The placebo-adjusted FVC change of +99 mL overall and +139 mL on background SOC, combined with a 60% relative reduction in accelerated FVC decline, suggests a repair phenotype rather than mere slowing of decline. This is the first time the company has shown concordant molecular, cellular, and clinical evidence of lung repair, which materially strengthens the case for advancing GRI-0621 into a longer-duration pivotal study. Against the backdrop of a going-concern warning and a market cap below Nasdaq's minimum listing threshold, positive data of this breadth is critical for the company's ability to raise the substantial capital needed for a Phase 2b/3 trial.